Recent Updates
Recently added Catalysts

GW876008

Phase 4

Irritable Bowel Syndrome (IBS) | Small molecule | Gastrointestinal |GSK plc|Trials Updated: Aug 19, 2026

GW876008 development status

Highest phase Phase 4 (NCT00259883)
Phase scored for GSKPhase 2
Registered trials 63 across 17 sponsors since Oct 2002

GW876008 target and mechanism

ModalitySmall molecule

Also known as GW876008 tablet, paroxetine, alprazolam, GSK561679

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials14
Total Enrollment1,970

FDA Designations

No designations recorded

GW876008 clinical trials

GW876008 · 14 trials · 10 indications

Phase 3 3Phase 2 6Phase 1 5
NCT00368303A Local Register Study For Major Depression Of Paroxetine Controlled ReleaseDepressive Disorder, Major
COMPLETED362 Analytics
NCT00067444Depression Study In Elderly PatientsDepressive Disorder, Major
COMPLETED560 Analytics
NCT00839397BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress DisorderPost-Traumatic Stress Disorder
COMPLETED52 Analytics
PHASE3COMPLETED
A Local Register Study For Major Depression Of Paroxetine Controlled Release
Depressive Disorder, MajorUnlock trial analytics
PHASE3COMPLETED
Depression Study In Elderly Patients
Depressive Disorder, MajorUnlock trial analytics
PHASE3COMPLETED
BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder
Post-Traumatic Stress DisorderUnlock trial analytics

Study Endpoints

Primary Endpoints

Scores on depression rating scale at treatment week 1,2,3,4,6 and 8.
Change from baseline to the week 10 last observation carried forward endpoint in the 17-item HAM-D total score.
10 Weeks
Change from baseline in the Clinician-Administered Posttraumatic Stress Disorder Scale One Week Symptom Status Version (CAPS-SX) total score
52 weeks
Change From Randomization to the End of Treatment Phase (Week 6) in the Bech Melancholia Subscale (Bech) (Items 1, 2, 7, 8, 10 and 13) From the Hamilton Rating Scale for Depression (HamD17).
Randomization (Week 0) and Week 6

The Bech Melancholia Sub-scale is extracted from the HAMD-17 and is comprised of the following 6 items: Depressed Mood, Feelings of Guilt, Work and Activities, Retardation, Anxiety Psychic, and Somatic Symptoms General. The items Depressed Mood, Feelings of Guilt, Work and Activities, Retardation, Anxiety Psychic are scored on a 5-point scale from 0 to 4 except for Somatic Symptoms General which is scored on a 3-point scale from 0 to 2 where the higher scores reflecting greater severity. The Bech Melancholia Scale total score is calculated by summing the individual response scores. The highest possible score is 22 (indicative of greater severity) and the lowest possible score is 0 (indicating absence of symptoms). Change from randomization was defined as the post-baseline value minus the value at randomization. Randomization was defined as Week 0.

Percent change from Baseline in Laser Doppler regional Rectal Mucosal Blood Flow (RMBF) measured in response to physiological stress (cold water pressor test)
Baseline (pre-dose) and Study Days 1, 2 and 3

Laser Doppler flowmetry measures changes in red cell flux using a probe that scans a fixed volume of tissue. Participants were examined in the left lateral position where DRT4 laser Doppler flow meter was placed against the rectal mucosa 10 centimeter (cm) above the lower limit of the anal margin, and pre-stress readings were taken after a period of 10 minutes of acclimatization in a room with an ambient temperature of 22 degrees Celsius. Physiological stress was evoked using the cold water pressor test. Participants were asked to place their hand and forearm into a container of ice-cold water at 0-4degree Celsius and were persuaded to maintain that position for as long as possible during the stress period of 10 minutes. Readings were then taken during pre-stress and at 5-minute intervals during the stress and recovery periods. Baseline was defined as the pre-dose assessment. Change from Baseline was calculated by subtracting the Baseline value minus the post-randomization value.

Percent Change from Baseline in Laser Doppler regional RMBF measured in response to psychological stress (dichotomous listening test)
Baseline (pre-dose) and Study Days 1, 2 and 3

Laser Doppler flowmetry measures changes in red cell flux using a probe that scans a fixed volume of tissue, an indirect measure of flow can be obtained. Participants were examined in the left lateral position with no prior bowel preparation. The laser Doppler probe (DRT4 laser Doppler flow meter) was then placed against the rectal mucosa 10 centimeter above the lower limit of the anal margin, and pre-stress readings were taken after a period of 10 minutes of acclimatization in a room with an ambient temperature of 22 degrees Celsius. The dichotomous listening test was used as a psychological stressor. At the onset of stress, folk music was played into one ear and rock music into the other ear for 10 minutes. Readings were then taken during pre-stress and at 5-minute intervals during the stress and recovery periods. Baseline was defined as the pre-dose assessment. Change from Baseline was calculated by subtracting the Baseline value minus the post-randomization value.

Change from randomization in the clinician-administered LSAS total score at the end of the treatment phase (Week 12)
Baseline (Day 0) and Week 12

The LSAS is an investigator-rated scale consisting of 48 questions concerning various social situations. The LSAS is the first psychiatric assessment at all post-screening visits. A qualified independent efficacy rater scored the participant's "fear or anxiety" and "avoidance" of social situations on 4-point scale : where, 0= None, 1= Mild, 2= Moderate, 3= Severe. Scores were recorded in participant's source documents. The LSAS total score was the sum of each of the forty-eight individual responses. Day 0 was Baseline and change from Baseline was calculated by subtracting Baseline value from Week 12 value. Data for adjusted mean and SE is presented.

Change from randomization on the LSAS Fear subscale score at Week 12
Baseline (Day 0) Week 12

The LSAS consisted of 24 fear responses. All individual items were rated on a scale 0 (none) -3 (severe) with higher scores indicating more severe fear. The LSAS fear subscale score was the sum of each of the 24 individual responses. If at least 22 items of the items making up the subscale of interest were present at a particular time point, the subscale score was calculated as Sum of non-missing items multiplied with 24/Number of non-missing items. If less than 22 of the items making up the score of interest were available for a participant at a particular time point, the subscale score was not calculated for that time point. Day 0 was Baseline and change from Baseline was calculated by subtracting Baseline value from Week 12 value. Data for adjusted mean and SE is presented.

Change from randomization on the LSAS Avoidance subscale score at Week 12
Baseline (Day 0) and Week 12

The LSAS consisted of 24 avoidance responses. All individual items were rated on a scale 0 (never) -3 (always) with higher scores indicating more severe avoidance. The LSAS avoidance subscale Score was the sum of each of the 24 individual responses. If at least 22 items of the items making up the subscale of interest were present at a particular time point, the total score was calculated as Sum of non-missing items multiplied with 24/Number of non-missing items. If less than 22 of the items making up the score of interest were available for a participant at a particular time point, the subscale score was not calculated for that time point. . Day 0 was Baseline and change from Baseline was calculated by subtracting Baseline value from Week 12 value. Data for adjusted mean and SE is presented.

Change from randomization on the Social Avoidance and Distress Scale (SADS) total score at Week 12
Baseline (Day 0) and Week 12

The SADS is a 28 item questionnaire. The total score was obtained by summing together the responses for all 28 items from the SADS questionnaire. Each individual item was rated as true or false. One point was given where items 2, 5, 8, 10, 11, 13, 14, 16, 18, 20, 21, 23, 24, 26 were marked as true and 1 point when each of the remaining items were marked as false. This gave a possible range of possible scores from 0 to 28 with higher scores indicating more severe disorder. If at least 26 of the items making up the total score were present at a particular time point, the total score was calculated as Sum of scores for non-missing items multiplied with 28/Number of non-missing items. If less than 26 of the items making up the score of interest were available for a participant at a particular time point, the total score was not calculated for that time point.

Number of Participants With Average Adequate Relief Rate During the Last 4 Weeks of the Treatment Periods (Weeks 3-6. in Period 1, Weeks 12-15 in Period 2).
Up to Day 105 (weeks 3-6. in period 1, weeks 12-15 in period 2)

For the assessment of average adequate relief rate from IBS symptoms for a participant was planned by collecting the response of a question 'In the past seven days have you had adequate relief of your IBS pain or discomfort? However, in error, the question was not collected in the IVRS system. Therefore, data for this endpoints was not collected during this study.

Number of Participants With Changes in Weekly Adequate Relief Rates During the Treatment Periods (Weeks 1-6 in Period 1 and Weeks 9-15 in Period 2).
Up to Day 105 (weeks 1-6 in period 1 and weeks 9-15 in period 2).

For the assessment of changes in weekly adequate relief rates during the treatment periods was planned by collecting the response of a question. Overall response was defined as having achieved adequate relief in last 4 weeks. However, in error, the question was not collected in the IVRS system. Therefore, data for this endpoints was not collected during this study.

Number of Participants With Adequate Relief of IBS Pain and Discomfort on All 4 of the Last 4 Weeks of the Treatment Phase Treatment Periods 1 and 2
Up to Day 105

For the assessment of average adequate relief rate from IBS symptoms for a participant was planned by collecting the response of a question whether weekly adequate relief from IBS symptoms was achieved?. However, in error, the question was not collected in the IVRS system. Therefore, data for this endpoints was not collected during this study.

Mean Global Improvement Scale (GIS) Responder Rate Over the Last Four Weeks by Regimen
Up to Day 105 (weeks 3-6 in period 1, weeks 12-15 in period 2)

The GIS is comprised of ten questions, all rated on a seven point scale ranging from substantially worse (7) to substantially improved (1). GIS assesses the participant's improvement (or worsening) as assessed by the clinician on a 7-point scale: 1: very much improved; 2: much improved; 3: minimally improved; 4: no change; 5: minimally worse; 6: much worse; or 7: very much worse for diarrhea, constipation, stool frequency, stool consistency, urgency, bloating, incomplete evacuation, and straining. Values reported are less than the minimum score on scale as the rate is the proportion of the last four weeks that the participant is a responder.

Ratings on Irritable Bowel Syndrome Quality of Life (IBSQoL) Scale
Up to Day 105 (weeks 3-6 in period 1, weeks 12-15 in period 2)

The IBSQoL is a self-report quality-of-life measure specific to IBS that can be used to assess the impact of IBS and its treatment. The IBSQoL consists of 30 statements about bowel problems, which formed 9 scales: emotional health, mental health, health belief, sleep, energy, physical functioning, diet, social role, physical role and sexual relation. All 9 scales were rated on a five-point response scale ranging from 1 (always) to 5 (never). Scores for individual items were averaged to obtain a total score for each subscale of IBSQoL. Then transformed to a 0-100 scale for ease of interpretation with higher scores indicating better IBS-specific quality of life. Transformed scale score = (raw score - lowest possible scale score)/ (scale range) X 100. The data presented for individual scale.

The primary outcome measure will be the change from baseline in the Liebowitz Social Anxiety Scale (LSAS)
Mean change from baseline in the Hamilton Anxiety Scale (HAM-A) total score (at Week 8, last observation carried forward [LOCF])
8 Weeks
Change From Baseline in Corrected QT Interval by Fridericia (QTcF Interval)
Baseline (Day -1); 0.25 Hours Pre-dose on Day 1; 1, 2, 3, 4, 4.5, 5, 5.5, 6, 8, 10, 12 Hours Post-dose on Day 1

A standard 12-lead electrocardiogram (ECG) were recorded in a participant using an ECG machine after 10 minutes rest in the supine position. Baseline was defined as the sample obtained on Day -1. Change from Baseline was calculated by subtracting Baseline value from post dose value.

Maximum Observed Plasma Concentration (Cmax) of Paroxetine
Pre-dose (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose

Blood samples were collected at indicated time points for the analysis of Cmax of Paroxetine. PK parameters were analyzed using non-compartmental analysis.

Area Under the Concentration-time Curve (AUC) From Time Zero to the Last Measurable Concentration (AUC[0-t]) of Paroxetine
Pre-dose (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose

Blood samples were collected at indicated time points for the analysis of AUC(0-t) of Paroxetine. PK parameters were analyzed using non-compartmental analysis.

Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Paroxetine
Pre-dose (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose

Blood samples were collected at indicated time points for the analysis of AUC(0-inf) of Paroxetine. PK parameters were analyzed using non-compartmental analysis.

Percentage of AUC (0 to Infinity) Obtained by Extrapolation (%AUCex) of Paroxetine
Pre-dose (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose

Blood samples were collected at indicated time points for the analysis of %AUCex of Paroxetine. PK parameters were analyzed using non-compartmental analysis.

Time of the Maximum Measured Plasma Concentration (Tmax) of Paroxetine
Pre-dose (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose

Blood samples were collected at indicated time points for the analysis of Tmax of Paroxetine. PK parameters were analyzed using non-compartmental analysis.

Elimination Half-life (t1/2) of Paroxetine
Pre-dose (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose

Blood samples were collected at indicated time points for the analysis of t1/2 of Paroxetine. PK parameters were analyzed using non-compartmental analysis.

Terminal Elimination Rate Constant (Kel) of Paroxetine
Pre-dose (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 12, 16, 24, 36, 48 and 72 hours post-dose

Blood samples were collected at indicated time points for the analysis of Kel of Paroxetine. PK parameters were analyzed using non-compartmental analysis.

Pharmacokinetic parameters of plasma paroxetine after 14-days repeat dosing of paroxetine CR at 25mg/day or paroxetine IR at 20mg/day
up to 96 hours after dosing on Day 14 of each treatment period of paroxetine CR or paroxetine IR
Changes of fMRI activation in amygdala of subjects with SAD during an emotional task after having received different compounds. Change in the VAS score in response to Public Speaking stress after having received different compounds.
over 6 weeks
Signal reductions in the amygdala during viewing of emotional faces and during abdominal pain threat as measured by the fMRI.
throughout the study

Secondary Endpoints

Scores on clinical impression severity and improvement items at treatment week 1, 2,3,4,6,8
Mean change from baseline in HAM-D item 1; Mean change from baseline in the CGI severity of illness score at study endpoint; Percentage of patients with HAM-D total score less than or equal to 7.
10 Weeks
Proportion of responders based on the CGI Global Improvement
52 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
ParoxetineOTHERA 52-week, non-comparative, uncontrolled study (However, the baseline phase is single blind)
GSK561679 armEXPERIMENTALDouble blind GSK561679
placebo armPLACEBO_COMPARATORDouble blind placebo
GW876008EXPERIMENTALGW876008
PlaceboPLACEBO_COMPARATORPlacebo
Paroxetine hydrochloride followed by PAXILEXPERIMENTAL -
PAXIL followed by paroxetine hydrochlorideEXPERIMENTAL -
Open label treatment with 2-period crossover designEXPERIMENTALGroup 1: Paroxetine CR 25 mg/day for 14 days / Paroxetine IR 20 mg/day for 14 days. Group 2: Paroxetine IR 20 mg/day for 14 days / Paroxetine CR 25 mg/day for 14 days., PK results will be compared between the Paroxetine CR treatment period and the Paroxetine IR treatment period.
GSK561679EXPERIMENTALThe subjects will be randomized to one of the six sequences A/C/D A/D/C C/A/D C/D/A D/A/C D/C/A across three treatment periods where A represents placebo, C represents GSK561679 and D represents alprazolam.
GW876008 20mcgEXPERIMENTALGW876008 20mcg
GW876008 200mcgEXPERIMENTALGW876008 200mcg

Interventions

NameTypeDescription
Paroxetine CRDRUG -
Paroxetine IRDRUG -
ParoxetineDRUGSubjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response ("1. Very much improved" or "2. Much improved" based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted. Dosage adjustment will be made at the discretion of the PI or Sub-PI
GSK561679DRUGGSK561679
PlaceboOTHERPlacebo
GW876008DRUG -
Paroxetine hydrochlorideDRUGParoxetine hydrochloride will be administered.
PAXIL (Paroxetine hydrochloride )DRUGPAXIL will be administered.
Paroxetine CR and Paroxetine IRDRUGRandomized, 2-period crossover repeat dosing of Paroxetine CR at 25 mg/day for 14 days and Paroxetine IR at 20 mg/day for 14 days in Japanese healthy male volunteers
GSK561679 tabletDRUGGSK561679 tablets are white film-coated tablets, containing 200 (milligrams) mg of the free base, GSK561679A.
GW876008 tabletDRUGGW876008 tablets are white to off-white round film-coated tablets, containing 100 mg of GW876008X (free base).
alprazolamDRUGAlprazolam capsules 0.25 mg are hard gelatine capsules containing 1 tablet of commercial alprazolam (Xanax 0.25).
GW876008 200mcgDRUGGW876008
GW876008 20mcgDRUGGW876008 20mcg
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites11

Inclusion Criteria: * Patients with Major Depressive Disorder,score on depression rating scale reach a specific point(17 item Hamilton Depression Scale\>18). Exclusion criteria: * patients use monoamine oxidase inhibitors (MAOIs), benzodiazepines, Chinese herbal medicines, acupuncture, moxibustio...

Countries:ChinaUnited StatesUnited KingdomCanadaFinlandGermanyNorwaySouth AfricaSwedenArgentinaChileCosta RicaMexicoJapanSpain
Unlock Eligibility Criteria

Competitive Landscape -Irritable Bowel Syndrome 15 trials (matched to "Irritable Bowel Syndrome (IBS)")

Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

MEDIUMSep 19, 2026NCT06065735TRIAL_REMOVED: changed
MEDIUMSep 19, 2026NCT06065735TRIAL_REMOVED: changed
MEDIUMSep 19, 2026NCT06065735TRIAL_REMOVED: changed

Frequently asked questions about GW876008

What is GW876008 used for?

GW876008 was studied for irritable bowel syndrome (IBS), irritable colon, and social phobia. It is an investigational small molecule developed by GSK plc and has been tested in Phase 2 clinical trials for these gastrointestinal and psychiatric conditions. It is not approved for any indication.

Who makes GW876008?

GW876008 is developed by GSK plc, which trades under the ticker GSK. The company sponsored the clinical trials investigating the drug in irritable bowel syndrome and social phobia.

What phase is GW876008 in?

GW876008 is in Phase 2 development. It has completed Phase 2 trials in irritable bowel syndrome and social phobia, as well as a Phase 1 study. It is an investigational drug and is not FDA approved.

What clinical trials is GW876008 in?

GW876008 has been studied in completed trials including NCT00421707 in irritable bowel syndrome, NCT00397722 in social anxiety disorder, NCT00385099 in irritable colon, and NCT00376896 in IBS patients and healthy volunteers. All trials are completed with no active studies ongoing.

How many patients were enrolled in GW876008 trials?

Across the completed clinical trials, GW876008 enrolled a total of 299 patients in the social phobia study, 133 in the irritable bowel syndrome trial, 10 in the irritable colon study, and 25 in the Phase 1 cerebral blood flow study. All trials were randomized, double-blind, and placebo-controlled.